FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016551235> ?p ?o ?g. }

• W2016551235 endingPage "955" @default.
• W2016551235 startingPage "944" @default.
• W2016551235 abstract "The D3 dopamine receptor selective antagonist PG01037 has been evaluated for the ability to attenuate l-dopa-associated abnormal involuntary movements (AIMs) in unilaterally lesioned male Sprague–Dawley rats, which is a model of l-dopa-dependent dyskinesia in patients with Parkinson's Disease. The intrinsic activity of PG01037 was determined using a) a forskolin-dependent adenylyl cyclase inhibition assay with transfected HEK 293 cells expressing either the human D2Long or D3 dopamine receptor subtype and b) an assay for agonist-associated mitogenesis. For the initial experiments, the 5-HT1A receptor selective partial agonist buspirone was used as a positive control to verify our ability to quantitate changes in total AIMs and AIMs minus locomotor scores. Subcutaneous (s.c.) administration of PG01037 was found to have minimal effect on AIMs score. However, it was observed that the in vivo efficacy of PG01037 increased when administered by intraperitoneal (i.p.) injection 15 min after l-dopa/benserazide administration, as compared to a 60 min, 30 min or 0 min pretreatment. It was also found that i.p. administration of PG01037 could inhibit involuntary movements after they had achieved maximum intensity. PG01037 was found to attenuate AIM scores in these animals in a dose dependent manner with IC50 value equal to a) 7.4 mg/kg following l-dopa/benserazide administration (8 mg/kg each, i.p.) and b) 18.4 mg/kg following the administration of apomorphine (0.05 mg/kg, s.c.). However, PG01037 did not effectively inhibit SKF 81297-dependent abnormal involuntary movements. Rotarod studies indicate that PG01037 at a dose of 10 mg/kg did not adversely affect motor coordination of the unilaterally lesioned rats. Evaluation of lesioned rats using a cylinder test behavioral paradigm indicated that PG01037 did not dramatically attenuate the beneficial effects of l-dopa. These studies suggest that D3 dopamine receptor selective antagonists are potential pharmacotherapeutic candidates for the treatment of l-dopa-associated dyskinesia in patients with Parkinson's Disease." @default.
• W2016551235 created "2016-06-24" @default.
• W2016551235 creator A5000283473 @default.
• W2016551235 creator A5001338370 @default.
• W2016551235 creator A5052807158 @default.
• W2016551235 creator A5059770390 @default.
• W2016551235 creator A5061926206 @default.
• W2016551235 creator A5090313381 @default.
• W2016551235 date "2009-05-01" @default.
• W2016551235 modified "2023-10-03" @default.
• W2016551235 title "Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats" @default.
• W2016551235 cites W1506920637 @default.
• W2016551235 cites W1507020912 @default.
• W2016551235 cites W1970571532 @default.
• W2016551235 cites W1972500026 @default.
• W2016551235 cites W1975667546 @default.
• W2016551235 cites W1981821582 @default.
• W2016551235 cites W198250404 @default.
• W2016551235 cites W1982511121 @default.
• W2016551235 cites W2000223105 @default.
• W2016551235 cites W2009028183 @default.
• W2016551235 cites W2013047529 @default.
• W2016551235 cites W2017424741 @default.
• W2016551235 cites W2017578012 @default.
• W2016551235 cites W2025102930 @default.
• W2016551235 cites W2029677994 @default.
• W2016551235 cites W2030360130 @default.
• W2016551235 cites W2030567881 @default.
• W2016551235 cites W2034945701 @default.
• W2016551235 cites W2038636807 @default.
• W2016551235 cites W2039209971 @default.
• W2016551235 cites W2051030373 @default.
• W2016551235 cites W2054617370 @default.
• W2016551235 cites W2063805684 @default.
• W2016551235 cites W2066340651 @default.
• W2016551235 cites W2068825785 @default.
• W2016551235 cites W2072572338 @default.
• W2016551235 cites W2076847033 @default.
• W2016551235 cites W2079085831 @default.
• W2016551235 cites W2085539182 @default.
• W2016551235 cites W2086483799 @default.
• W2016551235 cites W2088403433 @default.
• W2016551235 cites W2097863680 @default.
• W2016551235 cites W2103095851 @default.
• W2016551235 cites W2109307487 @default.
• W2016551235 cites W2114471594 @default.
• W2016551235 cites W2115613566 @default.
• W2016551235 cites W2118555630 @default.
• W2016551235 cites W2121928725 @default.
• W2016551235 cites W2131371182 @default.
• W2016551235 cites W2139106270 @default.
• W2016551235 cites W2140463558 @default.
• W2016551235 cites W2147493925 @default.
• W2016551235 cites W2154011816 @default.
• W2016551235 cites W2160360076 @default.
• W2016551235 cites W2161325655 @default.
• W2016551235 cites W2170920257 @default.
• W2016551235 cites W2337142316 @default.
• W2016551235 cites W85304509 @default.
• W2016551235 cites W953739412 @default.
• W2016551235 doi "https://doi.org/10.1016/j.neuropharm.2009.01.020" @default.
• W2016551235 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3820009" @default.
• W2016551235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19371585" @default.
• W2016551235 hasPublicationYear "2009" @default.
• W2016551235 type Work @default.
• W2016551235 sameAs 2016551235 @default.
• W2016551235 citedByCount "42" @default.
• W2016551235 countsByYear W20165512352012 @default.
• W2016551235 countsByYear W20165512352013 @default.
• W2016551235 countsByYear W20165512352014 @default.
• W2016551235 countsByYear W20165512352015 @default.
• W2016551235 countsByYear W20165512352016 @default.
• W2016551235 countsByYear W20165512352017 @default.
• W2016551235 countsByYear W20165512352018 @default.
• W2016551235 countsByYear W20165512352019 @default.
• W2016551235 countsByYear W20165512352021 @default.
• W2016551235 countsByYear W20165512352022 @default.
• W2016551235 crossrefType "journal-article" @default.
• W2016551235 hasAuthorship W2016551235A5000283473 @default.
• W2016551235 hasAuthorship W2016551235A5001338370 @default.
• W2016551235 hasAuthorship W2016551235A5052807158 @default.
• W2016551235 hasAuthorship W2016551235A5059770390 @default.
• W2016551235 hasAuthorship W2016551235A5061926206 @default.
• W2016551235 hasAuthorship W2016551235A5090313381 @default.
• W2016551235 hasBestOaLocation W20165512352 @default.
• W2016551235 hasConcept C120069818 @default.
• W2016551235 hasConcept C126322002 @default.
• W2016551235 hasConcept C134018914 @default.
• W2016551235 hasConcept C170493617 @default.
• W2016551235 hasConcept C185592680 @default.
• W2016551235 hasConcept C199596767 @default.
• W2016551235 hasConcept C2776885963 @default.
• W2016551235 hasConcept C2777525119 @default.
• W2016551235 hasConcept C2778122271 @default.
• W2016551235 hasConcept C2778938600 @default.
• W2016551235 hasConcept C2779026782 @default.
• W2016551235 hasConcept C2779134260 @default.
• W2016551235 hasConcept C2779734285 @default.

• next